Sanara MedTech Inc. (SMTI)

Market Cap	183.63M -35.8%
Revenue (ttm)	101.88M +30.5%
Net Income	-37.49M
EPS	-4.36
Shares Out	8.94M
PE Ratio	n/a
Forward PE	44.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,767
Open	22.00
Previous Close	22.05
Day's Range	20.50 - 22.43
52-Week Range	18.90 - 36.60
Beta	1.02
Analysts	Strong Buy
Price Target	41.00 (+99.51%)
Earnings Date	Nov 12, 2025

About SMTI

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a fre...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 141
• Stock Exchange: NASDAQ
• Ticker Symbol: SMTI
• Website: https://sanaramedtech.com

Financial Performance

In 2024, Sanara MedTech's revenue was $86.67 million, an increase of 33.36% compared to the previous year's $64.99 million. Losses were -$9.66 million, 124.6% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for SMTI stock is "Strong Buy." The 12-month stock price target is $41.0, which is an increase of 99.51% from the latest price.

Price Target

$41.0

(99.51% upside)

Analyst Consensus: Strong Buy